argenx to Present at JMP Securities Life Sciences Conference

argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced that its Chief Executive Officer, Tim Van Hauwermeiren, will participate in a panel discussion titled "Inflammation and Immunology: Restoring a Fine Balance" at the JMP Securities Life Sciences Conference on Tuesday, 20 June 2017 at 4:00 p.m. ET in New York City, NY.

Note

About argenx

argenx is a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. We are focused on developing product candidates with the potential to be either first-in-class against novel targets or best-in-class against known, but complex, targets in order to treat diseases with a significant unmet medical need. Our ability to execute on this focus is enabled by our suite of differentiated technologies. Our SIMPLE Antibody(TM) Platform, based on the powerful llama immune system, allows us to exploit novel and complex targets, and our three antibody engineering technologies are designed to enable us to expand the therapeutic index of our product candidates. 

www.argenx.com

For further information, please contact:

Joke Comijn, Corporate Communications Manager
+32 (0)477 77 29 44
+32 (0)9 310 34 19
info@argenx.com

Beth DelGiacco (US IR) Stern Investor Relations
+1 212 362 1200
beth@sternir.com

 

 

Interested in a regular update of the Life Sciences and biotech sector in Flanders?